These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 36285800)
1. Immunogenicity of a Live Dengue Vaccine (TAK-003). de Silva A; White L J Infect Dis; 2022 Dec; 227(1):163-164. PubMed ID: 36285800 [No Abstract] [Full Text] [Related]
5. Dengue vaccine prospects: a step forward. Guy B; Almond J; Lang J Lancet; 2011 Jan; 377(9763):381-2. PubMed ID: 21277439 [No Abstract] [Full Text] [Related]
6. Dengue vaccines: strongly sought but not a reality just yet. del Angel RM; Reyes-del Valle J PLoS Pathog; 2013; 9(10):e1003551. PubMed ID: 24098108 [No Abstract] [Full Text] [Related]
7. Dengue vaccines: state of the art. Swaminathan S; Batra G; Khanna N Expert Opin Ther Pat; 2010 Jun; 20(6):819-35. PubMed ID: 20384534 [TBL] [Abstract][Full Text] [Related]
8. Wanted Dead or Alive: A Correlate of Protection Against Dengue Virus. Gil L; Martín A; Lazo L Front Immunol; 2019; 10():2946. PubMed ID: 31921194 [No Abstract] [Full Text] [Related]
10. Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005. Durbin AP Curr Opin Virol; 2020 Aug; 43():79-87. PubMed ID: 33164790 [TBL] [Abstract][Full Text] [Related]
11. Development of Sanofi Pasteur tetravalent dengue vaccine. Lang J Rev Inst Med Trop Sao Paulo; 2012 Oct; 54 Suppl 18():S15-7. PubMed ID: 23011454 [No Abstract] [Full Text] [Related]
12. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial. Tricou V; Sáez-Llorens X; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Saldaña de Suman O; Montenegro N; DeAntonio R; Mazara S; Vargas M; Mendoza D; Rauscher M; Brose M; Lefevre I; Tuboi S; Borkowski A; Wallace D Lancet; 2020 May; 395(10234):1434-1443. PubMed ID: 32197107 [TBL] [Abstract][Full Text] [Related]
13. Characterization of the Type-Specific and Cross-Reactive B-Cell Responses Elicited by a Live-Attenuated Tetravalent Dengue Vaccine. Michlmayr D; Andrade P; Nascimento EJM; Parker A; Narvekar P; Dean HJ; Harris E J Infect Dis; 2021 Feb; 223(2):247-257. PubMed ID: 32572472 [TBL] [Abstract][Full Text] [Related]
14. Dengue vaccine: an update on recombinant subunit strategies. Martin J; Hermida L Acta Virol; 2016 Mar; 60(1):3-14. PubMed ID: 26982462 [TBL] [Abstract][Full Text] [Related]
15. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine. Galula JU; Shen WF; Chuang ST; Chang GJ; Chao DY J Virol; 2014 Sep; 88(18):10813-30. PubMed ID: 25008922 [TBL] [Abstract][Full Text] [Related]
16. DENGUE VACCINES. Thisyakorn U; Thisyakorn C Southeast Asian J Trop Med Public Health; 2015; 46 Suppl 1():138-45. PubMed ID: 26506740 [TBL] [Abstract][Full Text] [Related]
17. Current progress in dengue vaccines. Wan SW; Lin CF; Wang S; Chen YH; Yeh TM; Liu HS; Anderson R; Lin YS J Biomed Sci; 2013 Jun; 20(1):37. PubMed ID: 23758699 [TBL] [Abstract][Full Text] [Related]
18. The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection. Pitisuttithum P; Bouckenooghe A Expert Rev Vaccines; 2016 Jul; 15(7):795-8. PubMed ID: 27171845 [No Abstract] [Full Text] [Related]
20. Dengue: Status of current and under-development vaccines. Redoni M; Yacoub S; Rivino L; Giacobbe DR; Luzzati R; Di Bella S Rev Med Virol; 2020 Jul; 30(4):e2101. PubMed ID: 32101634 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]